In This Section      

Search Results

A011202 A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Protocol Number:
Phase III
Lisa Jacobs
Johns Hopkins Kimmel Cancer Center in Baltimore
Sibley Memorial Hospital
Suburban Hospital
The purpose of this study is to examine whether removing some of the lymph nodes from the arm pit, but not removing them all followed with radiation therapy (experimental) will be as good as having the majority of the lymph nodes from the arm pit removed during breast surgery followed with radiation (standard of care).
Generally healthy adults with breast cancer who had a positive lymph node, received neoadjuvant chemotherapy and then have clinically negative lymph nodes afterwards may be eligible.
Eligible subjects will undergo surgery with sentinel lymph node evaluation. Subjects with positive sentinel lymph node disease will be randomized to have nodal radiation therapy with either axillary lymph node dissection or axillary radiation therapy. Randomization means by chance, like flipping a coin. These subjects will be followed through their radiation therapy and up to 5 years afterward.
Last Update
08/07/2020 05:02 AM